Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rebenin
- Development stage
- Unknown
- Lead developer
- Novo Nordisk
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Rebenin is a brand name for Remimazolam Tosilate, an ultra-short-acting benzodiazepine. In China, Rebenin (Remimazolam Tosilate for Injection) is approved for general anesthesia and procedural sedation, including for gastrointestinal endoscopy and fiberoptic bronchoscopy. It functions by enhancing the inhibitory neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, leading to rapid onset and offset of sedation due to its quick metabolism by tissue esterases.
- Brand names
- Rebenin
- Other names
- remazolam toluenesulfonateRemimazolam Tosilate for InjectionRemimazolam Tosilate
02
Targets
GABRA2 (Gamma-aminobutyric acid receptor subunit alpha 2)
Beyond the preview
Go deeper on Rebenin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rebenin.